Rocket Pharmaceuticals, Inc. (RCKT): Shareholders' Equity
$277.22M
As of 2025-12-31
$368.83M
As of 2026-06-30
-17.3%
3-year compound annual growth
-11.3%
5-year compound annual growth
+9.8%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $277.22M | -40.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $463.23M | -6.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $492.57M | +0.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $489.69M | +7.7% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $454.72M | -9.7% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $503.52M | +63.9% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $307.30M | +58.4% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $194.04M | n/m | 2021-03-01, Balance as of period end |
| 2017-12-31 | $15.52M | +85.4% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $8.37M | -92.3% | 2019-03-08, Balance as of period end |
| 2015-12-31 | $108.81M | n/m | 2017-03-16, Balance as of period end |
| 2014-12-31 | -$51.56M | n/a | 2016-03-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $277.22M | -40.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare RCKT, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗